Raed Fahmy
Cardiovascular Disease · Gig Harbor, WANPI 1306988860
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,550 of the $39,909 with a category attached, or 61.5%. Johnson & Johnson accounts for 73.2% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $16,876 and has fallen 92.4% since, to $1,284 in 2025. Among cardiovascular disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 114 payments — averaging $350.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$29K
- Boston Scientific$3K
- Lilly USA, LLC$3K
- Amgen$706
- Boehringer Ingelheim$665
- Medtronic$654
- plus $3K from 18 others
Across 2 payments — averaging $3526.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$7K
What the payments were for
- Consulting fees$2,9257%
- Speaking & faculty fees$24,55062%
- Travel & lodging$4,97112%
- Food & beverage$7,45619%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 47 | $29,211 |
| Boston Scientific | 17 | $3,098 |
| Lilly USA, LLC | 1 | $2,625 |
| Amgen | 7 | $706 |
| Boehringer Ingelheim | 7 | $665 |
| Medtronic(2 entities) | 6 | $654 |
| Abbott | 5 | $623 |
| Novo Nordisk | 2 | $250 |
| AstraZeneca | 2 | $223 |
| Novartis | 3 | $219 |
| Abiomed | 2 | $212 |
| Kowa Pharmaceuticals America, Inc. | 2 | $209 |
| Pfizer | 2 | $154 |
| Shockwave Medical, Inc | 1 | $153 |
| Artivion, Inc. | 1 | $139 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Lexicon Pharmaceuticals, Inc. | 1 | $124 |
| Genentech USA, Inc. | 1 | $121 |
| Portola Pharmaceuticals, LLC | 1 | $120 |
| Astellas Pharma US Inc | 1 | $98 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $82 |
| Scpharmaceuticals Inc. | 1 | $56 |
| Siemens Medical Solutions USA, Inc. | 1 | $23 |
| Kestra Medical Technology Services, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$28,321
- JARDIANCE$2,997
- Watchman$1,312
- WATCHMAN Access System$1,204
- Ozempic$250
- WATCHMAN FLX$250
- CardioMEMS HF System$242
- CoreValve Evolut$238
- Repatha$224
- FARXIGA$223
- SelectSecure$189
- CARDIOMEMS$165
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$153
- Impella$147
- On-X$139
- NEXLIZET$125
- NEXLETOL$125
- Inpefa$124
- Activase$121
- ANDEXXA$120
How this compares
$39,909 in reported general payments places this provider in the 95th percentile of 370 cardiovascular disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 447 | $537,258 |
| EliquisApixaban | 185 | $265,195 |
| JardianceEmpagliflozin | 145 | $187,523 |
| EntrestoSacubitril/Valsartan | 77 | $116,135 |
| Repatha SureclickEvolocumab | 44 | $56,783 |
| FarxigaDapagliflozin Propanediol | 16 | $23,878 |
| MultaqDronedarone Hcl | 12 | $23,248 |
| Repatha PushtronexEvolocumab | 11 | $9,955 |
| Metoprolol Succinate | 588 | $8,703 |
| Atorvastatin Calcium | 648 | $7,306 |
| NexletolBempedoic Acid | 11 | $6,861 |
| Ezetimibe | 291 | $6,789 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $3,383 |
| Potassium Chloride | 138 | $3,121 |
| Midodrine Hcl | 29 | $2,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $29,211 | $537,258447 claims |
| PfizerEliquis | $154 | $265,195185 claims |
| Boehringer IngelheimJardiance | $665 | $187,523145 claims |
| NovartisEntresto | $219 | $116,13577 claims |
| AstraZenecaFarxiga | $223 | $23,87816 claims |
| Esperion Therapeutics, Inc.Nexletol | $125 | $6,86111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 370 cardiovascular disease providers in Washington.
Other cardiovascular disease in Gig Harbor
- Robert BersinBellevue$657K
- Mariko HarperSeattle$246K
- Gary OppenheimSeattle$153K
- Kelley BranchSeattle$103K
- Munish Kumar KannabhiranRichland$85K
- Erik WissnerSeattle$67K
- Younghoon KwonSeattle$66K
- Thomas AmidonBellevue$64K
- Aron BenderSeattle$60K
- Vidhushei YogeswaranSeattle$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.